Treatment with Obecabtagene Autoleucel Results in Durable Response Among Adults with Relapsed or Refractory B-Cell ALL By Ogkologos - December 12, 2024 179 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer MOST POPULAR FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer July 4, 2025 How Wartime Violence Against Women Is Hurting Millions Worldwide August 2, 2021 Many Patients with NSCLC Show Targetable Alterations in the PI3K Pathway March 24, 2021 Are New Immune-Based Treatments for Kidney and Pancreatic Cancer on the... April 23, 2025 Load more HOT NEWS No OS Benefit in EGFR T790M Advanced NSCLC Treated with Osimertinib... Woman Develops Breast Cancer After Double Mastectomy, Has to Have the... COVID-19 Pandemic Halts Cancer Care and Damages Oncologists’ Wellbeing [ESMO Press... Washington Farmers Harvest Crops For Neighbor With Stage Four Cancer
